High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation
- 10 November 2008
- journal article
- leukemia and-bone-marrow-transplantation
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (32), 5175-5182
- https://doi.org/10.1200/jco.2008.16.8294
Abstract
Purpose To develop high-dose myeloablative therapy for CD20+ non-Hodgkin's lymphoma (NHL) as a safe and widely applicable regimen. Patients and Methods Patients with relapsed/refractory (n = 25) or...Keywords
This publication has 25 references indexed in Scilit:
- Safety and Efficacy of Yttrium-90 Ibritumomab Tiuxetan in Older Patients With Non-Hodgkin's LymphomaCancer Biotherapy & Radiopharmaceuticals, 2007
- Yttrium 90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell LymphomaClinical Lymphoma, 2004
- Follow-Up Results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma and Mild ThrombocytopeniaCancer Biotherapy & Radiopharmaceuticals, 2004
- Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 studyBlood, 2004
- Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2003
- Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)Blood, 2003
- High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilizationBone Marrow Transplantation, 2002
- Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2002
- Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+B-Cell Non-Hodgkin's LymphomaJournal of Clinical Oncology, 1999
- GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR TO HARVEST CIRCULATING HAEMOPOIETIC STEM CELLS FOR AUTOTRANSPLANTATIONThe Lancet, 1989